A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer

CD22 is currently evaluated as a target-antigen for the treatment of B-cell malignancies using chimeric antigen receptor (CAR)-engineered T-cells or monoclonal antibodies (mAbs). CAR- and mAbs-based immunotherapies have been successfully applied targeting other antigens, however, occurrence of refra...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Jahn, Lorenz, Hagedoorn, Renate S., van der Steen, Dirk M., Hombrink, Pleun, Kester, Michel G.D., Schoonakker, Marjolein P., de Ridder, Daniëlle, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342099/
https://ncbi.nlm.nih.gov/pubmed/27689397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12247
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia